Orthopediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating restated by BTIG Research in a research report issued to clients and investors on Friday. They currently have a $24.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 19.70% from the stock’s current price.
A number of other brokerages have also weighed in on KIDS. Stifel Nicolaus began coverage on Orthopediatrics in a research note on Monday, November 6th. They set a “buy” rating and a $23.00 price target on the stock. Piper Jaffray Companies began coverage on Orthopediatrics in a research note on Monday, November 6th. They set an “overweight” rating and a $24.00 price target on the stock. Finally, William Blair began coverage on Orthopediatrics in a research note on Monday, November 6th. They set an “outperform” rating on the stock.
Shares of Orthopediatrics (NASDAQ KIDS) opened at $20.05 on Friday. Orthopediatrics has a 52 week low of $17.03 and a 52 week high of $23.00. The company has a quick ratio of 1.00, a current ratio of 2.78 and a debt-to-equity ratio of -0.38.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/orthopediatrics-kids-buy-rating-reaffirmed-at-btig-research.html.
Orthopediatrics Company Profile
OrthoPediatrics Corp. is a United States-based medical device company. The Company designs, develops and commercializes orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients. It operates through the OrthoPediatrics segment, which designs, develops and markets implants and devices for children with orthopedic problems.
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.